{"id":"NCT00275275","sponsor":"Rajesh Pahwa, MD","briefTitle":"Pramipexole Conversion to Ropinirole Controlled Release (CR)","officialTitle":"An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-01-11","resultsPosted":"2012-08-24","lastUpdate":"2012-08-24"},"enrollment":61,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Requip PR","otherNames":["Requip 24-hour prolonged release (PR)."]},{"type":"DRUG","name":"Mirapex","otherNames":["Pramipexole"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.","primaryOutcome":{"measure":"Adverse Effects Experienced","timeFrame":"Week 4","effectByArm":[{"arm":"Preferred Requip PR","deltaMin":29,"sd":null},{"arm":"Preferred Mirapex","deltaMin":43,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["PD worsening","Dizziness","Nausea","Somnolence","Anxiety"]}}